Werngard Czechtizky is Head of Medicinal Chemistry for Respiratory, Inflammation and Autoimmunity (RIA) at AstraZeneca in Gothenburg, Sweden. She has a track record of delivery of clinical candidates and lead compounds across several therapeutic areas (CV, Diabetes, Pain, CNS, Inflammation and Respiratory). Werngard has continuously implemented state of the art technologies into Medicinal Chemistry. These include e.g. efficient integration of machine learning methods into drug discovery projects, setup of New Modalities Medicinal Chemistry capabilities, implementation of automated synthesis, purification and analytics facilities and efficient integration of compound synthesis with physchem & eADME profiling to accelerate DMTA cycles. Werngard is part of AZ’s Global Chemistry Council, serves on scientific advisory boards of journals and conferences, and is co-/author of ca 80 publications and patents. She has studied at the Technical University of Graz, Austria, received a PhD from ETH Zürich and a postdoctoral training at Harvard University. Before joining AZ in 2017, she has been Head of Chemistry at Sanofi Frankfurt, Germany.
Title to be announced
Dr Nir LONDON
THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Discovery of Risdiplam (Evrysdi): A Medicine for the Treatment of Spinal Muscular Atrophy
Dr Hasane RATNI
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland Read more
Dr Hasane RATNI
Dr H. Ratni is an Distinguished Scientist, Medicinal Chemistry, at F. Hoffmann-La Roche Ltd., Basel, Switzerland. He successfully, bring from early research to the clinic 6 molecules, one already successfully launched.
He received his PhD at the University of Geneva and did a post-doc at Tokyo University before joining F. Hoffmann-La Roche Ltd in 2001. His research has mainly been devoted to the areas of neuroscience (e.g. V1a receptor antagonist, in human clinical trials, phase 3, for autism). In 2005, he participated in a secondment within the Roche group at Chugai Pharmaceutical Co. Ltd, Gotemba Japan. He was the chemistry discovery project leader of the SMN program for the treatment of spinal muscular atrophy, and inventor of Risdiplam (Evrysdi) approved by FDA in August 2020. His current focus is on gamma secretase modulator for Alzheimer disease.
He is an author or co-author of more than 115 patents and publications and received the following awards: - 2014: Roche Leo Sternbach Award for Innovation in Chemistry.
- 2016: Gold medal at the Roche Patent Inventor’s recognition event.
- 2019: Paper of the year award by the Society of Toxicology (DDTSS)
- 2020: Roche CEO Award for Excellence
- 2020: Senior Industrial Science Award by the Swiss Chemical Society (SCS)